Compare ADMA Biologics Inc (ADMA) vs Lufax Holding Ltd (LU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Lufax Holding Ltd — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Lufax Holding Ltd trades at $1.39 (market cap $2.41B). The key difference: ADMA Biologics Inc and Lufax Holding Ltd are close in size by market cap. Which is the better fit depends on your goals.
| ADMA | LU | |
|---|---|---|
Market Cap | $2.13B | $2.41B |
Sector | Health | Technology |
52-Week High | $20.38 | $4.40 |
52-Week Low | $7.60 | $1.23 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
LU trades at $1.42, up 1.43% today, with a bullish technical signal but bearish moving averages. The stock shows deep value with a P/S of 0.36 and P/B of 0.1, yet profitability is weak with a -9.08% net margin and negative ROE. Recent news is dominated by a securities class action lawsuit with a May 20, 2026 deadline, creating significant headline risk.
The outlook is mixed; low valuations and a bullish analyst consensus (61.5% buy ratings) suggest potential upside, but negative earnings, cash flow challenges, and legal overhang present substantial risks. Investor sentiment is cautious due to the litigation, making near-term performance highly dependent on case developments and future earnings delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
